I noticed this “Special Article” published in the October edition of the British Journal of Psychiatry. It details a novel antipsychotic medication called Lurasidone (trade name Latuda). I would anticipate that this is the start of a programme to educate psychiatrists in the UK on this new drug.
I note from the ProPublica Searchable database that one of the authors of this “Special Article” has received payments from the drug’s manufacturers as below:
